SCHEMBL26658235

SCHEMBL26658235

Cc1ccc(-c2csc(NC(=O)c3ccn(C)n3)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.59
▸ SMN1; SMN2 Q16637 5/20 0.59
▸ KDM4E B2RXH2 4/20 0.59
▸ NPC1 O15118 3/20 0.59
▸ RAB9A P51151 3/20 0.59
▸ MAPT P10636 8/20 0.58
▸ HTT P42858 2/20 0.58
▸ MEN1 O00255 5/20 0.57
▸ KMT2A Q03164 5/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ POLB P06746 3/20 0.57
▸ ESR1 P03372 1/20 0.57
▸ ESR2 Q92731 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ GSTO1 P78417 1/20 0.56
▸ MITF O75030 1/20 0.55
▸ NTSR1 P30989 1/20 0.55
▸ THRB P10828 1/20 0.54
▸ GAA P10253 1/20 0.51
▸ RECQL P46063 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26884172 0.89 MEN1 (0.54) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL26884180 0.89 KMT2A (0.61) LMNASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL24330744 0.89 PARP1 (0.57) LMNASMN1; SMN2MAPTHTTMEN1
SCHEMBL24329679 0.87 MEN1 (0.62) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL24329836 0.85 MAPT (0.50) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL24329676 0.84 MAPT (0.53) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL26884264 0.83 LMNA (0.51) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL24329687 0.82 LMNA (0.58) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL26884220 0.81 SMN1; SMN2 (0.48) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL26884174 0.81 HDAC3 (0.53) LMNASMN1; SMN2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
WO-2023205366-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS CARTHRONIX, INC. (US) 2023-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 LMNA 4496/4885SMN1; SMN2 4696/4885KDM4E 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback